Home / Health / UK Mothers Battle Bureaucracy for Lifesaving Cannabis Meds
UK Mothers Battle Bureaucracy for Lifesaving Cannabis Meds
14 May
Summary
- Two mothers fought UK bureaucracy for child cannabis medicine.
- Most patients now pay high private costs for access.
- Medical cannabis legality shifted but NHS access remains difficult.
In the UK, mothers Hannah Deacon and Charlotte Caldwell battled extensive bureaucracy to obtain cannabis-based medicines for their children suffering from severe epilepsy. Alfie Deacon's seizures began at eight months old, leading to a challenging diagnosis of PCDH19 epilepsy. His mother's persistent advocacy eventually led to a groundbreaking prescription in 2018.
Despite the legalisation of medical cannabis in the UK in June 2018, its accessibility remains a significant challenge. Only a handful of prescriptions have been issued by the NHS, with the vast majority of patients resorting to expensive private clinics, costing up to £1,000 per month.
Historically, cannabis research and use in the UK faced significant hurdles, influenced by international drug control policies from the early 20th century. The creation of the NHS in 1948 and subsequent shifts in medical standardization marginalized alternative treatments.
Currently, the medical cannabis landscape in the UK is largely driven by private sector profit. While public awareness campaigns educate about potential benefits, the system often prioritizes financial gain over equitable patient access, leaving many struggling with prohibitive costs.
